Parallax Volatility Advisers
DMAAR

Parallax Volatility Advisers’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Parallax Volatility Advisers’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-87,926
Closed -$19.1K – 1884
2025
Q3 		$19.1K Buy
+87,926
New +$16.3K ﹤0.01% 1511

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
HCI
Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

Parallax Volatility Advisers's DMAAR Position: Q4 2025 in Review

Parallax Volatility Advisers sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q4 2025, closing a stake of 87,926 shares — an estimated $19.1K sold.

Parallax Volatility Advisers first reported a position in DMAAR in Q3 2025 and held it in 1 quarter. The position peaked at $19.1K in Q3 2025. 32 funds tracked by Wall St. Rank hold DMAAR as of Q4 2025.

  • Parallax Volatility Advisers reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q4 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 87,926 Drugs Made In America Acquisition Corp Rights shares in Q4 2025, an estimated $19.1K.
  • Parallax Volatility Advisers first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and held it in 1 quarter.
  • Parallax Volatility Advisers's Drugs Made In America Acquisition Corp Rights position peaked at $19.1K in Q3 2025.
  • 32 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q4 2025.

Based on Parallax Volatility Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.